Show simple item record

dc.contributor.authorManchia, Mirko
dc.contributor.authorVieta, Eduard
dc.contributor.authorSmeland, Olav B.
dc.contributor.authorAltimus, Cara
dc.contributor.authorBechdolf, Andreas
dc.contributor.authorBellivier, Frank
dc.contributor.authorBergink, Veerle
dc.contributor.authorFagiolini, Andrea
dc.contributor.authorGeddes, John
dc.contributor.authorHajek, Tomas
dc.contributor.authorHenry, Chantal
dc.contributor.authorKupka, Ralph
dc.contributor.authorLagerberg, Trine V.
dc.contributor.authorLicht, Rasmus W.
dc.contributor.authorMartínez Cengotitabengoa, Mónica ORCID
dc.contributor.authorMorken, Gunnar
dc.contributor.authorNielsen, René E.
dc.contributor.authorGonzález Pinto Arrillaga, Ana María ORCID
dc.contributor.authorReif, Andreas
dc.contributor.authorRietschel, Marcella
dc.contributor.authorRitter, Philipp
dc.contributor.authorSchulze, Thomas G.
dc.contributor.authorScott, Jan
dc.contributor.authorSeverus, Emanuel
dc.contributor.authorYildiz, Aysegul
dc.contributor.authorKessing, Lars Vedel
dc.contributor.authorBauer, Michael
dc.contributor.authorGoodwin, Guy M.
dc.contributor.authorAndreassen, Ole A.
dc.date.accessioned2020-08-07T07:52:13Z
dc.date.available2020-08-07T07:52:13Z
dc.date.issued2020-06-12
dc.identifier.citationEuropean Neuropsychopharmacology 36 : 121–136 (2020)es_ES
dc.identifier.issn0924-977X
dc.identifier.urihttp://hdl.handle.net/10810/45906
dc.description.abstract[EN] Bipolar disorder (BD) is a major healthcare and socio-economic challenge. Despite its substan- tial burden on society, the research activity in BD is much smaller than its economic impact appears to demand. There is a consensus that the accurate identification of the underlying pathophysiology for BD is fundamental to realize major health benefits through better treat- ment and preventive regimens. However, to achieve these goals requires coordinated action and innovative approaches to boost the discovery of the neurobiological underpinnings of BD, and rapid translation of research findings into development and testing of better and more spe- cific treatments. To this end, we here propose that only a large-scale coordinated action can be successful in integrating international big-data approaches with real-world clinical inter- ventions. This could be achieved through the creation of a Global Bipolar Disorder Foundation, which could bring government, industry and philanthropy together in common cause. A global initiative for BD research would come at a highly opportune time given the seminal advances promised for our understanding of the genetic and brain basis of the disease and the obvious areas of unmet clinical need. Such an endeavour would embrace the principles of open science and see the strong involvement of user groups and integration of dissemination and public involvement with the research programs. We believe the time is right for a step change in our approach to understanding, treating and even preventing BD effectively.es_ES
dc.description.sponsorshipWe thank Chris Chang for input on the description of the ENIGMA project. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health in the UK. Ole A. Andreassen is together with Paolo Fusar-Poli co-chairing the Prevention of Severe Mental Disorders (PSMD) cluster, which is supported by the European Brain Research Area project. EBRA has re- ceived funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 825348 .es_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.relationinfo:eu-repo/grantAgreement/EC/H2020/825348es_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjectmachine learninges_ES
dc.subjectopen sciencees_ES
dc.subjectphilanthropyes_ES
dc.subjectprecision medicinees_ES
dc.subjectrisk predictiones_ES
dc.titleTranslating big data to better treatment in bipolar disorder - a manifesto for coordinated actiones_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.holder© 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license ( http://creativecommons.org/licenses/by/4.0/ )es_ES
dc.relation.publisherversionhttps://www.sciencedirect.com/science/article/pii/S0924977X20301802?via%3Dihub#!es_ES
dc.identifier.doi10.1016/j.euroneuro.2020.05.006
dc.contributor.funderEuropean Commission
dc.departamentoesFarmacia y ciencias de los alimentoses_ES
dc.departamentoesNeurocienciases_ES
dc.departamentoeuFarmazia eta elikagaien zientziakes_ES
dc.departamentoeuNeurozientziakes_ES


Files in this item

Thumbnail
Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

© 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license ( http://creativecommons.org/licenses/by/4.0/ )
Except where otherwise noted, this item's license is described as © 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license ( http://creativecommons.org/licenses/by/4.0/ )